The epidermal growth factor receptor (EGFR) has long been known to be responsible for causing triple-negative breast cancer , and several drugs have been tested over the years trying to target it. However, they all had one major limitation — they were unable to target selected cancer cells without affecting the healthy cells. Researchers at the University of Arizona have developed a peptide-based therapeutic drug, cSNX1.3 that blocks EGFR from reaching the part of the cell that drives the survival of cancer. The compound shuts down the function of the EGFR protein in cancer cells while causing no harm to healthy cells.
When tested in mouse models, the drug not only stopped the tumor growth but also caused them to regress and go away without any toxic side effects. Besides human trials, it would be interesting to see in the future if the drug can suppress metastasis as well. Can…
